Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChesnara Regulatory News (CSN)

Share Price Information for Chesnara (CSN)

Share Price is delayed by 15 minutes
Get Live Data
317.50    0.50 (0.16%)
Bid:
315.50
Ask:
317.00
Spread: 1.50 (0.475%)
Market Cap: £732.37m
CSN Live PriceLast checked at - London Stock Exchange

Intraday Chesnara Share Chart

Director/PDMR Shareholding

26 Nov 2021 13:00

RNS Number : 7435T
Chesnara PLC
26 November 2021
 

CHESNARA plc

("Chesnara" or "the Company")

 

26 November 2021

 

LEI Number: 213800VFRMBRTSZ3SJ06

 

 

NOTIFICATION OF TRANSACTIONS OF DIRECTORS / PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY ('PDMRs')

 

Further to the appointment of Steve Murray as Group Chief Executive on 19 October 2021, Chesnara plc (the 'Company') today announces that, under the terms of his appointment, Steve (a PDMR) was granted awards in the ordinary shares of the Company under the Chesnara plc 2014 Long-Term Incentive Scheme to compensate him for remuneration arrangements forfeited on leaving his former employer, The Royal London Mutual Insurance Society Limited. These awards were made in accordance with the Company's Directors' Remuneration Policy and are subject to the Executive Directors' Minimum Shareholding Policy.

 

The notification below, which is being made in accordance with the requirements of Article-19 of the EU Market Abuse Regulation 596/2014 as retained in UK law by virtue of the European Union (Withdrawal) Act 2018, provides further detail of the awards granted.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

b)

Natural person:

Legal person

Steven Grant Murray

2

Reason for the notification

a)

Position/status:

Executive Director and Group Chief Executive

b)

Initial notification/amendment

Initial notification

3

Details of the Issuer

a)

Name

Chesnara plc

b)

Legal Entity Identifier:

213800VFRMBRTSZ3SJ06

4

Details of the transaction(s): Parts a-d of this section are to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.

a)

Description of the financial instrument, type of instrument (Identification code)

Chesnara plc Ordinary Shares of 5 pence each

(GB00B00FPT80)

b)

Nature of the transaction

GRANT 1

Granted under the Chesnara 2014 Long-term Incentive Scheme. The option is subject to a performance target ending 31 December 2021.

 

Subject to the achievement of the performance target, the option will become exercisable on 31 December 2021 and remain exercisable up to and including 26 November 2031 if not exercised before that date.

 

GRANT 2

Granted under the Chesnara 2014 Long-term Incentive Scheme. The option is subject to a performance target ending 31 December 2021.

 

Subject to the achievement of the performance target, the option will become exercisable on 30 June 2022 and remain exercisable up to and including 26 November 2031 if not exercised before that date.

 

GRANT 3

Granted under the Chesnara 2014 Long-term Incentive Scheme. The option is subject to a performance target ending 31 December 2022.

 

Subject to the achievement of the performance target, the option will become exercisable on 31 December 2022 and remain exercisable up to and including 26 November 2031 if not exercised before that date.

GRANT 4

Granted under the Chesnara 2014 Long-term Incentive Scheme. The option is subject to performance targets ending 31 December 2022.

 

Subject to the achievement of the performance target, the option will become exercisable on 30 April 2023 and remain exercisable up to and including 26 November 2031 if not exercised before that date.

 

GRANT 5

Granted under the Chesnara 2014 Long-term Incentive Scheme. The option is subject to performance targets ending 30 June 2023.

 

Subject to the achievement of the performance target, the option will become exercisable on 30 June 2023 and remain exercisable up to and including 26 November 2031 if not exercised before that date.

 

GRANT 6

Granted under the Chesnara 2014 Long-term Incentive Scheme. The option is subject to performance targets ending 31 December 2023.

 

Subject to the achievement of the performance target, the option will become exercisable on 30 April 2024 and remain exercisable up to and including 26 November 2031 if not exercised before that date.

 

GRANT 7

Granted under the Chesnara 2014 Long-term Incentive Scheme. The option is subject to performance targets ending 31 December 2023.

 

Subject to the achievement of the performance target, the option will become exercisable on 30 June 2024 and remain exercisable up to and including 26 November 2031 if not exercised before that date.

 

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

GRANT 1

50,456 Ordinary shares of 5p each

Nil

GRANT 2

119,089 Ordinary shares of 5p each

Nil

GRANT 3

50,456 Ordinary shares of 5p each

Nil

GRANT 4

119,089 Ordinary shares of 5p each

Nil

GRANT 5

20,722 Ordinary shares of 5p each

Nil

GRANT 6

140,105 Ordinary shares of 5p each

Nil

GRANT 7

33,625 Ordinary shares of 5p each

d)

Aggregated information

- Aggregated volume

- Price

 

- 533,542 ORDINARY SHARES OF 5P EACH

- Nil

e)

Date of the transaction (YYYY - MM - DD)

2021-11-26

f)

Place of the transaction

XOFF

 

 

Name of authorised official of issuer responsible for making notification: - Al Lonie

 

Date of notification: - 26 November 2021

 

For further information, please contact:

 

Roddy Watt

Director, Capital Markets

FWD

Forward thinking communications

 

T - 020 7280 0651

E - roddy.watt@fwdconsulting.co.uk 

 

 

Notes to Editors

Chesnara is a life and pensions company listed on the London Stock Exchange. It administers approximately 900,000 policies and operates as Countrywide Assured in the UK, as The Waard Group and Scildon in the Netherlands, and as Movestic in Sweden.

 

Following a three-pillar strategy, Chesnara's primary responsibility is the efficient administration of its customers' life and savings policies, ensuring good customer outcomes and providing a secure and compliant environment to protect policyholder interests. It also adds value by writing profitable new business in Sweden and the Netherlands and by undertaking value-adding acquisitions of either companies or portfolios.

 

Consistent delivery of the Company strategy has enabled Chesnara to increase its dividend for 17 years in succession.

 

Further details are available on the Company's website (www.chesnara.co.uk).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHPPGBPGUPGGUQ
Date   Source Headline
24th Oct 20227:00 amRNSBlock listing Interim Review
19th Oct 20227:00 amRNSDirector/PDMR Shareholding
3rd Oct 20227:00 amRNSAppointment of Group GC & Company Secretary
29th Sep 20227:00 amRNSBlock Listing Application
12th Sep 20227:15 amEQSHardman & Co Research on Chesnara Plc (CSN): Robust cash generation in challenging markets
8th Sep 202212:05 pmEQSHardman Talks Video: Interview Chesnara management discuss 2022 half-year results
2nd Sep 20227:00 amRNSHolding(s) in Company
31st Aug 20227:00 amRNSHalf-year Report
23rd Aug 20227:00 amRNSHolding(s) in Company
17th Aug 20227:00 amRNSNotice of Interim Results
15th Aug 20222:45 pmEQSHardman & Co: Q&A on Chesnara Plc (CSN) Conservatrix acquisition boosts AuA and cash flow with capacity for more
8th Aug 20227:00 amRNSHolding(s) in Company
5th Aug 20227:00 amRNSHolding(s) in Company
2nd Aug 20227:00 amRNSChesnara Enhances M&A and Commercial Capabilities
29th Jul 20227:15 amEQSHardman & Co Research: Chesnara plc (CSN): Another fine acquisition
22nd Jul 20227:00 amRNSAcquisition
16th Jun 20229:15 amEQSHardman & Co Research: Q&A on Chesnara Plc (CSN): Good performance analysed
31st May 20227:00 amRNSTotal Voting Rights
24th May 20227:00 amEQSHardman & Co Research : Chesnara plc (CSN): Market benefits overwhelm operational challenges
17th May 20221:51 pmRNSResult of AGM
29th Apr 20227:00 amRNSDirector/PDMR Shareholding
28th Apr 20227:00 amRNSAcquisition Completions
22nd Apr 20227:00 amRNSBlock listing Interim Review
21st Apr 20227:00 amRNSNotice of AGM
8th Apr 20227:00 amRNSAcquisition Update
5th Apr 20222:30 pmRNSDirector/PDMR Shareholding
31st Mar 20227:00 amRNSFinal Results
17th Mar 20227:00 amRNSNotice of Results
15th Mar 20227:00 amRNSTotal Voting Rights
14th Feb 20227:00 amRNSDirectorate Change
2nd Feb 20223:07 pmRNS£200m Inaugural Tier 2 Subordinated Notes Issuance
26th Jan 20227:00 amRNSHolding(s) in Company
17th Jan 20227:00 amRNSDirectorate Change
17th Dec 20217:00 amRNSSenior Leadership Appointment
9th Dec 20217:00 amRNSHolding(s) in Company
2nd Dec 20211:50 pmEQSHardman & Co Research : Chesnara (CSN) Initiation of Coverage: Could be the least worrying dividend you'll get
26th Nov 20211:00 pmRNSDirector/PDMR Shareholding
25th Nov 20217:00 amRNSAcquisition
22nd Oct 20217:00 amRNSBlock listing Interim Review
19th Oct 20217:00 amRNSDirectorate Change
13th Sep 20217:00 amRNSProposed Acquisition
7th Sep 20217:00 amRNSHolding(s) in Company
26th Aug 20217:00 amRNSHalf-year Report
12th Aug 20217:00 amRNSNotice of Results
2nd Aug 20217:00 amRNSDirectorate Change
28th May 20214:36 pmRNSHolding(s) in Company
28th May 20217:00 amRNSTotal Voting Rights
21st May 20217:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
18th May 20213:30 pmRNSResult of AGM
12th May 20217:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.